Heidelberg Pharma AG today published its financial results and Annual Report for fiscal year 2024 (1 December 2023 – 30 November 2024) and its outlook for 2025.
– Promising data from clinical trial with HDP-101 in multiple myeloma, including a complete remission in one female patient; study is making good progress
– Received first approvals for the clinical study with ATAC candidate HDP-102; study to start soon
– Financials according to plan with improved operating result and lower cash use requirements
– Payment of USD 20 million from HealthCare Royalty significantly extends cash runway
– Conference call to be held on 24 March 2025 at 02:00 pm CET / 09:00 am EDT